钠-葡萄糖协同转运蛋白2抑制剂与心力衰竭的临床研究进展  

Sodium-glucose Cotransporter 2 Inhibitor and Heart Failure

作　　者：廖崇米 刘剑雄 蒋昭隆 LIAO Chongmi;LIU Jianxiong;JIANG Zhaolong(Zunyi Medical University Graduate School,Zunyi 563003,Guizhou,China;Department of Cardiology,Chengdu Second People’s Hospital Affiliated with Zunyi Medical University,Chengdu 610017,Sichuan,China)

机构地区：[1]遵义医科大学研究生院,贵州遵义563003 [2]遵义医科大学附属成都市第二人民医院心血管内科,四川成都610017

出　　处：《心血管病学进展》2020年第2期118-121,共4页Advances in Cardiovascular Diseases

摘　　要：糖尿病是心血管事件的独立危险因素,心血管疾病合并糖尿病时增加患者死亡风险。新型降糖药钠-葡萄糖协同转运蛋白2抑制剂被证实可显著降低糖尿病患者的心血管死亡率和心力衰竭住院率,机制可能与降低心脏负荷、改善心脏能量代谢和改善心肌重构等相关。现阐述钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭防治方面最新的研究进展,为心力衰竭的治疗提供新思路。Diabetes is an independent risk factor for cardiovascular events,and cardiovascular disease with diabetes increases the risk of death.The novel sodium-glucose cotransporter 2 inhibitor has been shown to significantly reduce the cardiovascular mortality and hospitalization rate of heart failure in diabetic patients,and the mechanism may be related to the reduction of cardiac load,improvement of cardiac energy metabolism and myocardial remodeling.This article reviews the latest research progress of sodium-glucose cotransporter 2 inhibitors in the prevention and treatment of heart failure,providing a new idea for the treatment of heart failure.

关 键 词：心力衰竭 钠-葡萄糖协同转运蛋白2 抑制剂 2型糖尿病 

分 类 号：R541.6[医药卫生—心血管疾病]